AI Innovation Hub Launched
April 2024 – Bern AI Research Center
We opened our dedicated AI research center in Bern, Switzerland, focused on accelerating drug discovery and screening through cutting-edge computational modeling. The center collaborates closely with both academic and industrial partners. It marks a major leap in our R&D capabilities.
Go-to-market
September 2021 – Proof-of-Concept Validated
The proof-of-concept for our market activities was successfully established in collaboration with top pharmaceutical brands across major markets. This validated both the scalability and competitiveness of our technologies. It also laid the foundation for broader adoption of our CDMO services. The milestone confirmed the market’s readiness for our CDMO peptide services.
GMP Facility Grand Opening
June 2021 – Taizhou Production Plant
We celebrated the opening of our large-scale GMP peptide API manufacturing plant in Taizhou, China. Designed for industrial-scale synthesis, the facility significantly expanded our global production capacity. It features advanced equipment for both clinical and commercial supply. This marked a critical step in scaling our operations worldwide.
Custom Synthesis Expansion
April 2021 – Zhangzhou Facility Established
To meet growing demand for tailored peptide solutions, we launched a dedicated custom synthesis facility in Zhangzhou. In collaboration with the Xiamen university this site specializes in rapid-response peptide custom synthesis in research quantities. The facility enhances our flexibility and turnaround speed for research-scale and pre-clinical development batches. It complements our broader CDMO infrastructure.
Rapid Pandemic Response
2020 – COVID-19 Peptide Case Study
During the COVID-19 outbreak, we rapidly developed a peptide-based fusion inhibitor candidate. This showcased our ability to quickly pivot resources and apply expertise in urgent therapeutic development. The project highlighted the versatility of our platform and responsiveness in public health emergencies. It remains a proud example of science in action.
New Frontiers in Drug Design
2019 – Chemical Space Theory Applied
We applied novel chemical space theory to expand the landscape of peptide drug discovery. This approach enabled our capabilities to identify unique structural motifs with therapeutic potential. It deepened our understanding of structure-activity relationships. A step forward in unlocking new classes of bioactive peptides for our clients.
Mid-Scale Manufacturing Milestone
2016 – Pilot Plant Commissioned
Our first mid-scale peptide manufacturing pilot plant (50 kg/year capacity) became operational in 2016. The plant allowed us to bridge the gap between lab-scale synthesis and industrial production. It enabled process development, optimization, and scale-up under one roof. This laid the groundwork for future GMP expansion.
Our Origins in Innovation
2013 – Technology Transfer from Uni Bern
Space Peptides was founded through a technology transfer from Prof. Reymond’s group at the University of Bern. The transfer included proprietary know-how in computational chemistry and novel peptide synthesis methods. This academic foundation continues to inform our scientific approach. It represents the start of our journey from idea to industry leadership.
You must be logged in to post a comment.